Skip to main content

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

CBE ID
0083e
1.4 Project
Endorsement Status
1.1 New or Maintenance
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Spring 2025
1.3 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

        • 1.14 Numerator

          Patients who were prescribed beta-blocker therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

        • 1.15 Denominator

          All patients aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF < 40%

        • Exclusions

          Denominator Exceptions:
          Documentation of medical reason(s) for not prescribing beta-blocker therapy (e.g., low blood pressure, fluid overload, asthma, patients recently treated with an intravenous positive inotropic agent, allergy, intolerance, other medical reasons).

          Documentation of patient reason(s) for not prescribing beta-blocker therapy (e.g., patient declined, other patient reasons).

          Documentation of system reason(s) for not prescribing beta-blocker therapy (e.g., other reasons attributable to the healthcare system).

        • Most Recent Endorsement Activity - OLD
          Endorsed Cardiovascular Spring Cycle 2019
          Initial Endorsement
          Last Updated
        • Steward
          American College of Cardiology
          Steward Organization POC Email
          Steward Organization Copyright

          Copyright 2019 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.